As of January 22, 2025, BioAtla (BCAB) has a market cap of $28.925 million USD. According to our data, BioAtla is ranked No.8426 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $28.93 M |
-15.65%
|
Dec 31, 2024 | $34.29 M |
-75.98%
|
Dec 29, 2023 | $0.14 B |
-70.18%
|
Dec 30, 2022 | $0.48 B |
-57.97%
|
Dec 31, 2021 | $1.14 B |
-42.28%
|
Dec 31, 2020 | $1.97 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
MacroGenics
MGNX
|
$0.19 B |
-0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
ADC Therapeutics
ADCT
|
$0.16 B |
-0.000 M
|
Switzerland
|
Mersana Therapeutics
MRSN
|
$65.16 M |
0.000 M
|
USA
|
Sutro Biopharma
STRO
|
$0.16 B |
-0.000 M
|
USA
|
I-Mab Biopharma
IMAB
|
$87.21 M |
-0.000 M
|
China
|
Pieris Pharmaceuticals
PIRS
|
$17.96 M |
0.000 M
|
USA
|
CytomX Therapeutics
CTMX
|
$65.57 M |
0.000 M
|
USA
|
Avidity Biosciences
RNA
|
$3.59 B |
-0.000 M
|
USA
|
Nektar Therapeutics
NKTR
|
$0.17 B |
0.000 M
|
USA
|
Xencor
XNCR
|
$1.45 B |
0.000 M
|
USA
|
AbCellera
ABCL
|
$1.04 B |
0.000 M
|
Canada
|
Market Cap | = | BCAB Stock Price | * | BCAB Shares Outstanding |
= | $0.50 | * | 58.02 M | |
= | $28.93 M |